#1 Attorneys Network
Experts from the firm’s life sciences group have assisted the global pharmaceutical company, AstraZeneca on a significant transaction.
MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, announced on 3 March an agreement to develop and commercialise MEDI8897 jointly. MEDI8897 is a monoclonal antibody for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV), the most prevalent cause of LRTI among infants and young children.
Patrick Duxbury, a partner in the Gowling WLG life sciences team team worked with AstraZeneca Senior Counsel Sarah Jackson on the transaction.
The post Gowling advises AstraZeneca on Sanofi deal appeared first on The Lawyer | Legal News and Jobs | Advancing the business of law.
#1 Attorneys Search Engine